
Health Issues | |
Fraser Study: Living Standards, Not Price Controls, Lead To Different Drug Prices |
Canada's lower prescription drug prices are due to a lower standard of living relative to the United States, not Canadian drug price regulation, concludes a new study from Canada's Fraser Institute. Researchers John Graham and Beverley Robson compared American and Canadian wholesale and retail prices for the top 60 drugs, ranked by prescriptions written in the United States. Of the 45 drugs they found to be comparable:
Canadians get a smaller discount for patented drugs than name brand, non-patented drugs. This is interesting since Canadian prices are controlled for patented drugs, but not non-patented drugs. The weighted average price of uncontrolled drugs was 65 percent lower in Canada, whereas price controlled drugs were 35 percent cheaper. Over time, the price differential between Canadian drug prices and those in the U.S. and other developed countries has widened -- as the gap in living standards has increased:
Source: John R. Graham and Beverley A. Robson, "Prescription Drug Prices in Canada and the United States -- Part 1: A Comparative Survey; Part 2: Why the Difference?" Public Policy Sources, September 2000, Fraser Institute, 4th Floor, 1770 Burrard Street, Vancouver, BC, Canada, V6J 3G7, (604) 688-0221. For text http://www.fraserinstitute.org/commerce.web/publication_details.aspx?pubID=2514 For more on Health Policies http://www.ncpa.org/iss/hea/ |